Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Arthur Website

Diane C. Arthur, M.D.

Selected Publications

1)  Arthur DC, Bloomfield CD, Lindquist LL, Nesbit ME.
Translocation 4; 11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance.
Blood. 59: 96-9, 1982.
2)  Arthur DC, Bloomfield CD.
Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association.
Blood. 61: 994-8, 1983.
3)  Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Cancer Res. 58: 4173-9, 1998.
4)  Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Blood. 101: 4944-51, 2003.
5)  Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM.
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.
Blood. 123: 809-21, 2014.
6)  Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ.
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
Exp. Hematol. 41: 772-8, 2013.
7)  Stetler-Stevenson M, DiGiuseppe J, Arthur D.
Kottke-Marchant K, Davis B, eds.
Myelodysplastic Disorders. In: Laboratory Hematology Practice.
West Sussex: Wiley-Blackwell; 2012. p. 331-344 [Book Chapter]
8)  Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Bcl-2 level as a biomarker for 13q14 deletion in CLL.
Cytometry B Clin Cytom. 84: 237-47, 2012.
9)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Combined normal donor and CLL: Single tube ZAP-70 analysis.
Cytometry B Clin Cytom. 82: 67-77, 2012.
10)  Shah NN, Bacher U, Fry T, Calvo KR, Stetler-Stevenson M, Arthur DC, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy NM, Wayne AS.
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: Diagnostic and therapeutic challenges.
Am. J. Hematol. 87: 916-22, 2012.
11)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wiestner A, Stetler-Stevenson MA, Marti GE.
Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation.
Cytometry B Clin. Cytom. 80: 309-17, 2011.
12)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Methodological comparison of two anti-ZAP-70 antibodies.
Cytometry B Clin. Cytom. 80: 300-8, 2011.
13)  Calvo KR, Vinh DC, Maric I, Wang W, Noel P, Stetler-Stevenson M, Arthur DC, Raffeld M, Dutra A, Pak E, Myung K, Hsu AP, Hickstein DD, Pittaluga S, Holland SM.
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.
Haematologica. 96: 1221-5, 2011.
14)  Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Blood. 117: 563-74, 2011.
15)  Taylor JG, Darbari DS, Darari DS, Maric I, McIver Z, Arthur DC.
Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.
Ann. Intern. Med. 155: 722-4, 2011.
16)  Raygada M, Arthur DC, Wayne AS, Rennert OM, Toretsky JA, Stratakis CA.
Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia.
Pediatr Blood Cancer. 54: 173-5, 2010.
17)  Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC, Maric I, Noel P, Kocabas C, Marynen P, Lessin LS, Wlodarska I, Robyn J, Metcalfe DD.
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.
Haematologica. 93: 49-56, 2008.
18)  Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ, Watson MS, Arthur DC, Tantravahi R, Heerema NA, Koduru PR, Block AW, Qumsiyeh MB, Edwards CG, Sterling LJ, Holland KB, Bloomfield CD.
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.
Int. J. Oncol. 33: 239-44, 2008.
19)  Mussai FJ, Cunningham LC, Rezvani G, Stratakis CA, Reynolds JC, Nesterova G, Henshaw RM, Levine JE, Helman LJ, Arthur DC, Kim SY.
Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome.
J. Pediatr. Hematol. Oncol. 30: 612-7, 2008.
20)  Ng D, Toure O, Wei MH, Arthur DC, Abbasi F, Fontaine L, Marti GE, Fraumeni JF, Goldin LR, Caporaso N, Toro JR.
Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia.
Blood. 109: 916-25, 2007.
21)  Caruccio L, Bettinotti M, Director-Myska AE, Arthur DC, Stroncek D.
The gene overexpressed in polycythemia rubra vera, PRV-1, and the gene encoding a neutrophil alloantigen, NB1, are alleles of a single gene, CD177, in chromosome band 19q13.31.
Transfusion. 46: 441-7, 2006.
22)  Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM.
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Blood. 104: 1428-34, 2004.
23)  Robyn J, Noel P, Wlodarska I, Choksi M, O'neal P, Arthur D, Dunbar C, Nutman T, Klion A.
Imatinib-responsive hypereosinophilia in a patient with B cell ALL.
Leuk Lymphoma. 45: 2497-2501, 2004.
24)  Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD.
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
J Clin Oncol. 22: 1087-94, 2004.
25)  Dusenbery KE, Howells WB, Arthur DC, Alonzo T, Lee JW, Kobrinsky N, Barnard DR, Wells RJ, Buckley JD, Lange BJ, Woods WG.
Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group.
J Pediatr Hematol Oncol. 25: 760-8, 2003.
26)  Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M.
Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.
Lab Invest. 83: 1255-65, 2003.
27)  Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB 8461) .
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Blood. 100: 4325-36, 2002.
28)  Wells RJ, Arthur DC, Srivastava A, Heerema NA, Le Beau M, Alonzo TA, Buxton AB, Woods WG, Howells WB, Benjamin DR, Betcher DL, Buckley JD, Feig SA, Kim T, Odom LF, Ruymann FB, Smithson WA, Tannous R, Whitt JK, Wolff L, Tjoa T, Lampkin BC.
Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213.
Leukemia. 16: 601-7, 2002.
29)  Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, Sanders J, Neudorf S, Gold S, Lange BJ.
Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group.
J Clin Oncol. 20: 434-40, 2002.
30)  Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, Lange BJ, Kobrinsky NL, Children's Cancer Group .
A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.
Blood. 97: 56-62, 2001.
31)  Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME.
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.
Blood. 98: 979-87, 2001.
32)  Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE.
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.
Blood. 98: 2518-25, 2001.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/11/2014.